Physician profile
Amber M Lesley
NPI 1679782908
$3,114.79
in general payments reported to CMS, 2019-2025
26 companies · $999 in 2025
The $999 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.48 · 2020: $82.22 · 2021: $270 · 2022: $195 · 2023: $333 · 2024: $1,152 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,484.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $599.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $418.70 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.20 | 2021-2025 | Jardiance |
| Amgen INC. | $278.81 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $249.20 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $156.42 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $123.95 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $120.61 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $104.42 | 2022-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $94.39 | 2024-2025 | Inspire |
| Pfizer INC. | $76.05 | 2024-2025 | |
| Abbvie INC. | $75.81 | 2021-2025 | |
| Nevro Corp. | $65.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $56.33 | 2019-2025 | Spravato |
| Hologic Sales and Service, LLC | $41.54 | 2025 | Aptima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrocision, INC. | $41.45 | 2022 | |
| Astellas Pharma US INC | $31.46 | 2019-2025 | Veozah |
| Genentech USA, INC. | $29.99 | 2019-2020 | |
| Medtronic, INC. | $23.50 | 2025 | Symplicity G3 |
| Ibsa Pharma INC. | $22.45 | 2024 | Licart, Tirosint |
| Bayer Healthcare Pharmaceuticals INC. | $17.27 | 2024 | |
| Csl Behring | $16.48 | 2024 | Haegarda |
| Xeris Pharmaceuticals, INC. | $14.46 | 2023 | Keveyis |
| Azurity Pharmaceuticals, INC. | $14.15 | 2024 | |
| Ethicon US, LLC | $13.61 | 2019 | |
| Merck Sharp & Dohme LLC | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Lesley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.